Drug intelligence / Profile preview

bushenning pian

Development stage: Unknown
Lead developer: Nanjing Gaitianli Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Bushenning Pian is a Traditional Chinese Medicine (TCM) tablet developed and marketed by Nanjing Gaitianli Pharmaceutical, a subsidiary of the Xiuzheng Pharmaceutical Group. It is formulated to tonify the kidney, replenish vital essence, and calm the nerves. The medication is primarily indicated for patients suffering from kidney deficiency, which manifests as dizziness, tinnitus, palpitations, insomnia, and weakness or soreness in the lower back and knees. The formulation consists of a complex blend of herbal extracts, including Rehmannia glutinosa and Cornus officinalis, which are traditionally used to restore physiological balance and support renal and reproductive health.

Brand names: GaitianliXiuzheng
Other names: Bushenning Tablets

Beyond the preview

Go deeper on bushenning pian.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bushenning pian.

Explore the full profile